Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Breast Neoplasms 2Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Thyroid Diseases 1Ovarian Neoplasms 1Neoplasms 1Lung Neoplasms 1Kidney Neoplasms 1

Interventions

selpercatinib 2Sorafenib 2vandetanib 1temsirolimus 1pralsetinib 1pembrolizumab 1lenvatinib 1cabozantinib 1Vitamin B 12 1Thyrotropin-Releasing Hormone 1Technetium Tc 99m Sestamibi 1Pemetrexed 1Panobinostat 1NAc-Sar-Gly-Val-(d-allo-Ile)-Thr-Nva-Ile-Arg-ProNEt 1Metformin 1Folic Acid 1Fluorescein 1Cisplatin 1Cetuximab 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Thyroid Diseases × Technetium Tc 99m Sestamibi × Clear all
NCT03065218 2022-07-26

99mTc Sestamibi Scans In Thyroglobulin Positive Scan Negative Differentiated Thyroid Cancer (DTC) Patients

Medstar Health Research Institute

Phase 4 Terminated
4 enrolled 5 charts
Head & Neck

Thyroid Diseases, Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡